DGX vs EBS · P/E 22, rev $9.87B vs rev $1.04B
Quest Diagnostics Incorporated (DGX) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported DGX revenue for 2024-12-31 was $9.87B. Net income was $921.0M. Revenue was up 6.7% from 2023-12-31 to 2024-12-31. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. EBS currently screens at market cap $416.4M.
Not investment advice. Open the DGX and EBS stock pages for the full models.
Not investment advice.